Study: Actemra better than placebo in late-stage trial

11/20/2009 | Reuters

More patients who took Roche Holding's Actemra had reduced signs and symptoms of systemic onset juvenile idiopathic arthritis than those given placebo after 12 weeks of treatment in a Phase III trial. The finding adds to evidence of Actemra's efficacy for arthritis, including another late-stage study that showed the drug prevented further joint damage in patients with rheumatoid arthritis.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT